CN116785369A - Traditional Chinese medicine compound for treating obesity type oligospermia, preparation method and application thereof - Google Patents
Traditional Chinese medicine compound for treating obesity type oligospermia, preparation method and application thereof Download PDFInfo
- Publication number
- CN116785369A CN116785369A CN202311010577.6A CN202311010577A CN116785369A CN 116785369 A CN116785369 A CN 116785369A CN 202311010577 A CN202311010577 A CN 202311010577A CN 116785369 A CN116785369 A CN 116785369A
- Authority
- CN
- China
- Prior art keywords
- parts
- oligospermia
- traditional chinese
- chinese medicine
- medicine compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 48
- 206010003883 azoospermia Diseases 0.000 title claims abstract description 37
- 208000008634 oligospermia Diseases 0.000 title claims abstract description 37
- 230000036616 oligospermia Effects 0.000 title claims abstract description 37
- 231100000528 oligospermia Toxicity 0.000 title claims abstract description 37
- 208000008589 Obesity Diseases 0.000 title claims abstract description 35
- 150000001875 compounds Chemical class 0.000 title claims abstract description 35
- 235000020824 obesity Nutrition 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 239000002775 capsule Substances 0.000 claims abstract description 16
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 13
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 13
- 241001522129 Pinellia Species 0.000 claims abstract description 13
- 244000197580 Poria cocos Species 0.000 claims abstract description 13
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 13
- 235000011034 Rubus glaucus Nutrition 0.000 claims abstract description 13
- 244000235659 Rubus idaeus Species 0.000 claims abstract description 13
- 235000009122 Rubus idaeus Nutrition 0.000 claims abstract description 13
- 235000008434 ginseng Nutrition 0.000 claims abstract description 13
- 244000061520 Angelica archangelica Species 0.000 claims abstract description 12
- 241000132012 Atractylodes Species 0.000 claims abstract description 12
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 12
- 235000017784 Mespilus germanica Nutrition 0.000 claims abstract description 12
- 244000182216 Mimusops elengi Species 0.000 claims abstract description 12
- 235000000560 Mimusops elengi Nutrition 0.000 claims abstract description 12
- 235000007837 Vangueria infausta Nutrition 0.000 claims abstract description 12
- 235000003805 Musa ABB Group Nutrition 0.000 claims abstract description 10
- 240000008790 Musa x paradisiaca Species 0.000 claims abstract description 10
- 235000015266 Plantago major Nutrition 0.000 claims abstract description 10
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 241000202726 Bupleurum Species 0.000 claims abstract description 9
- 235000021028 berry Nutrition 0.000 claims abstract description 8
- 229940107666 astragalus root Drugs 0.000 claims abstract description 6
- 241000206501 Actaea <angiosperm> Species 0.000 claims abstract description 4
- 240000007371 Cuscuta campestris Species 0.000 claims abstract description 3
- 238000001914 filtration Methods 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 241000208340 Araliaceae Species 0.000 claims description 12
- 241001061264 Astragalus Species 0.000 claims description 12
- 235000006533 astragalus Nutrition 0.000 claims description 12
- 210000000582 semen Anatomy 0.000 claims description 12
- 210000004233 talus Anatomy 0.000 claims description 12
- 241000906579 Actaea cimicifuga Species 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 7
- 240000006079 Schisandra chinensis Species 0.000 claims description 5
- 235000008422 Schisandra chinensis Nutrition 0.000 claims description 5
- 238000002791 soaking Methods 0.000 claims description 4
- 241000201895 Salicornia Species 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 1
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 abstract description 22
- 229960003604 testosterone Drugs 0.000 abstract description 11
- 102000016267 Leptin Human genes 0.000 abstract description 9
- 108010092277 Leptin Proteins 0.000 abstract description 9
- 229940039781 leptin Drugs 0.000 abstract description 9
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 abstract description 9
- 210000001550 testis Anatomy 0.000 abstract description 9
- 230000001575 pathological effect Effects 0.000 abstract description 7
- 210000002966 serum Anatomy 0.000 abstract description 6
- 235000009200 high fat diet Nutrition 0.000 abstract description 4
- 238000012360 testing method Methods 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 238000009776 industrial production Methods 0.000 abstract description 2
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 19
- 210000003734 kidney Anatomy 0.000 description 14
- 229940079593 drug Drugs 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- 239000000463 material Substances 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 9
- 206010062717 Increased upper airway secretion Diseases 0.000 description 6
- 238000009835 boiling Methods 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 208000026435 phlegm Diseases 0.000 description 6
- 238000005728 strengthening Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 201000010063 epididymitis Diseases 0.000 description 5
- 230000008506 pathogenesis Effects 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 206010033307 Overweight Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000000918 epididymis Anatomy 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000007466 Male Infertility Diseases 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000000920 spermatogeneic effect Effects 0.000 description 3
- 241000721047 Danaus plexippus Species 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 210000000579 abdominal fat Anatomy 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000019100 sperm motility Effects 0.000 description 2
- 230000002381 testicular Effects 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000213006 Angelica dahurica Species 0.000 description 1
- 206010067162 Asthenospermia Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 206010061199 Head deformity Diseases 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000030120 acrosome reaction Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000013264 cohort analysis Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000062 effect on obesity Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000037219 healthy weight Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000013227 male C57BL/6J mice Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000575 proteomic method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002477 vacuolizing effect Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/43—Cuscutaceae (Dodder family), e.g. Cuscuta epithymum or greater dodder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Reproductive Health (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine compound for treating obesity type oligospermia, a preparation method and application thereof. The preparation raw materials of the traditional Chinese medicine compound comprise the following components: ginseng, astragalus root, bupleurum, angelica, bighead atractylodes rhizome, cimicifuga rhizome, dried orange peel, poria cocos, pinellia tuber, fried dodder, medlar, raspberry, shizandra berry and salted plantain seed. The beneficial effects of the invention are as follows: the traditional Chinese medicine compound can obviously reduce the weight, fat index and leptin level of an obese oligospermia mouse caused by high-fat diet, improve the testosterone level in serum of the mouse, effectively improve the sperm quality and pathological conditions of testes, and has certain advantages in improving the sperm quality compared with the traditional Chinese patent medicine compound capsule which is clinically used at present, so that the traditional Chinese medicine compound has the function of excellently treating the obese oligospermia. The traditional Chinese medicine compound preparation method is simple, low in equipment requirement, strong in operability and suitable for industrial production and application.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicines, and in particular relates to a traditional Chinese medicine compound for treating obesity type oligospermia, a preparation method and application thereof.
Background
Obesity is a pathological condition resulting from excessive accumulation of fat, usually measured in terms of Body Mass Index (BMI), 25kg/m 2 ≤BMI＜30kg/m 2 Is overweight, and the BMI is more than or equal to 30kg/m 2 Is obese. With the prevalence of unhealthy lifestyles such as excessive intake of sugar and fat, reduced physical activity, sedentary, etc., the incidence of obesity has increased rapidly, and the World Health Organization (WHO) of 2016 has shown that 39% of men 18 years and older are overweight, about 11% obese.
Research shows that overweight or obesity is closely related to male infertility, and sperm quality tends to decrease along with body mass index increase, so that sperm density and activity decrease, sperm morphology and acrosome reaction abnormality, membrane lipid change and DNA damage increase can be caused; ramaraju et al performed retrospective cohort analysis on 1285 male patients, found that obesity was closely related to lower sperm volume, density, motility, and higher sperm head deformity, with obese men more susceptible to oligospermia and asthenospermia; proteomic analysis found that there was a significant difference in the abundance of 27 proteins in obese men's sperm compared to healthy weight men, indicating that overweight resulted in significant changes in sperm proteomes, and that obesity could potentially produce molecular changes to sperm even though there was no significant difference in semen parameters. Obesity type oligospermia has become one of the main causes of male infertility. Because the pathogenesis of the oligospermia is not completely clear, the modern medicine mostly adopts therapies such as weight losing, lipid lowering, blood sugar lowering, hormone level regulating and the like, belongs to empirical and experimental treatment, still lacks effective treatment means, explores the pathogenesis of the oligospermia due to obesity, and searches for effective treatment ways and medicines, which are important problems to be solved urgently.
Disclosure of Invention
In view of the defects of the prior art, the invention provides a traditional Chinese medicine compound for treating obesity type oligospermia, a preparation method and application thereof. The invention is based on the etiology and pathogenesis of obesity oligospermia, and the reasonable compatibility formula is carried out from the three aspects of strengthening spleen, tonifying kidney and resolving phlegm, and is verified by the modern experimental technical means, so that the compound has good treatment effect, provides technical support for further development and utilization, and is expected to be applied to the development of male infertility treatment medicines.
Spleen deficiency failing to transport and transform, food essence failing to transform into food, and essence and qi failing to spread, the kidneys store innate essence without nourishment; the congenital deficiency of the kidney deficiency causes spleen yang not to warm up; deficiency of both spleen and kidney results in no kidney being hidden, and is prone to phlegm-dampness, further affecting the generation of reproductive sperm and rendering the hidden sperm impure, so that infertility occurs. Therefore, spleen-kidney deficiency with phlegm-dampness is the basic pathogenesis of obese oligospermia.
Based on the basic pathogenesis of the obesity oligospermia, the invention treats the obesity oligospermia from the angles of strengthening spleen, tonifying kidney and reducing phlegm, reduces weight, fat index and leptin level, improves testosterone level in serum, and effectively improves sperm quality and pathological conditions of testes, thereby achieving the effect of treating both symptoms and root causes and presenting unique advantages in the treatment of the obesity oligospermia.
Specifically, the invention provides a traditional Chinese medicine compound for treating obesity type oligospermia, which is prepared from the following raw materials: ginseng, astragalus root, bupleurum, angelica, bighead atractylodes rhizome, cimicifuga rhizome, dried orange peel, poria cocos, pinellia tuber, fried dodder, medlar, raspberry, shizandra berry and salted plantain seed.
The traditional Chinese medicine compound prescription of the invention is as follows: atractylodis rhizoma, rhizoma Atractylodis Macrocephalae, has effects of invigorating qi and spleen, eliminating dampness and promoting diuresis; astragalus root, radix astragali, having the effects of invigorating qi and raising yang, and tonifying defensive and consolidating superficial resistance; semen cuscutae, capable of tonifying kidney, inducing astringency, replenishing essence and strengthening bones; fructus Lycii, nourishing liver and kidney, and replenishing essence and blood; the four drugs are all monarch drugs and are combined to treat the diseases of strengthening spleen, tonifying qi, tonifying kidney and producing sperm. Ginseng, poria cocos, dried orange peel and pinellia tuber have the effects of strengthening spleen, tonifying qi, eliminating dampness and resolving phlegm; the Chinese angelica is combined with astragalus root to show the effect of activating blood and promoting qi circulation; raspberry tonifies the kidney, invigorates yang, and consolidates kidney and astringes essence; the schisandra chinensis has the effects of tonifying kidney and stopping nocturnal emission, and the two auxiliary drugs strengthen the kidney, and the seven auxiliary drugs are used as ministerial drugs. Bupleurum root and cimicifuga rhizome are used for lifting yang and sinking, and monarch drugs are used for lifting sinking middle warmer; semen plantaginis has the effects of promoting diuresis and removing turbid urine, and is used as an adjuvant drug for preventing greasy feeling. The medicines are combined to play a role in strengthening spleen, tonifying qi, tonifying kidney, generating essence, drying dampness and resolving phlegm.
As a specific embodiment of the invention, the preparation raw materials of the traditional Chinese medicine compound comprise the following components in parts by weight: 6-9 parts of ginseng, 6-9 parts of astragalus, 1-3 parts of radix bupleuri, 6-9 parts of angelica, 20-30 parts of bighead atractylodes rhizome, 1-2 parts of cimicifuga foetida, 1-3 parts of dried orange peel, 10-15 parts of poria cocos, 5-9 parts of pinellia ternate, 12-16 parts of fried semen cuscutae, 12-16 parts of medlar, 6-8 parts of raspberry, 1-2 parts of schisandra chinensis and 2-4 parts of salted plantain seed.
As a specific embodiment of the invention, the preparation raw materials of the traditional Chinese medicine compound comprise the following components in parts by weight: 9 parts of ginseng, 9 parts of astragalus, 3 parts of bupleurum, 9 parts of angelica, 30 parts of bighead atractylodes rhizome, 2 parts of cimicifuga foetida, 3 parts of dried orange peel, 15 parts of poria cocos, 9 parts of pinellia ternate, 16 parts of fried semen cuscutae, 16 parts of medlar, 8 parts of raspberry, 2 parts of shizandra berry and 4 parts of salted plantain seed.
As a specific embodiment of the invention, the astragalus is raw astragalus.
The preparation form of the traditional Chinese medicine compound is any one of decoction, granules, pills, paste, tablets and capsules.
As a specific implementation mode of the invention, the traditional Chinese medicine compound preparation is a decoction.
In another aspect of the invention, a preparation method of a traditional Chinese medicine decoction for treating obesity oligospermia is provided: the components are taken according to the following weight proportion: 6-9 parts of ginseng, 6-9 parts of raw astragalus, 1-3 parts of radix bupleuri, 6-9 parts of angelica, 20-30 parts of bighead atractylodes rhizome, 1-2 parts of cimicifuga foetida, 1-3 parts of dried orange peel, 10-15 parts of poria cocos, 5-9 parts of pinellia ternate, 12-16 parts of fried semen cuscutae, 12-16 parts of medlar, 6-8 parts of raspberry, 1-2 parts of schisandra chinensis and 2-4 parts of salicornia asiatica, decocting in water, and filtering to obtain filtrate.
As a specific embodiment of the invention, each component is taken, soaked after water is added until the components are soaked, decocted for 30-35 min, filtered, water is added again to filter residues until the components are soaked, and then decocted again for 15-20 min, filtered, and the filtrates obtained after the two times of filtering are combined.
In another aspect, the invention provides application of the traditional Chinese medicine compound in preparing a medicine for treating obesity oligospermia.
In another aspect, the invention provides application of the traditional Chinese medicine compound in preparing a medicine for treating obesity.
The beneficial effects of the invention are as follows:
1. the traditional Chinese medicine compound can obviously reduce the weight, fat index and leptin level of an obese oligospermia mouse caused by high-fat diet, improve the testosterone level in serum of the mouse, effectively improve the sperm quality and pathological conditions of testes, and has certain advantages in improving the sperm quality compared with the traditional Chinese patent medicine compound capsule which is clinically used at present, so that the traditional Chinese medicine compound has the function of excellently treating the obese oligospermia.
2. The traditional Chinese medicine compound preparation method is simple, low in equipment requirement, strong in operability and suitable for industrial production and application.
Drawings
Figure 1 is a comparison of body weight of each group of high fat diet fed mice over time (±s, n=16);
fig. 2 is the effect of each group on abdominal fat of high fat feed fed mice (±s, n=16);
fig. 3A is a comparison of sperm density for each group (±s, n=6);
fig. 3B is a comparison of sperm motility (±s, n=6) for each group;
FIG. 4A is a comparison of total cholesterol for each group;
FIG. 4B is a comparison of total cholesterol esters for each group;
fig. 4C is a comparison of testosterone for each group;
FIG. 4D is a comparison of leptin in each group;
FIG. 5 shows the effect of pathological conditions in groups of high fat fed mice.
Detailed Description
For the purpose of making the objects, technical solutions and advantages of the embodiments of the present invention more apparent, the technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings in the embodiments of the present invention, and it is apparent that the described embodiments are some embodiments of the present invention, but not all embodiments of the present invention. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
Example 1
A Chinese medicinal decoction for treating obesity type oligospermia is prepared from the following raw materials: 9g of ginseng, 9g of raw astragalus, 3g of bupleurum, 9g of angelica, 30g of bighead atractylodes rhizome, 2g of cimicifuga foetida, 3g of dried orange peel, 15g of poria cocos, 9g of pinellia ternate, 16g of fried semen cuscutae, 16g of medlar, 8g of raspberry, 2g of shizandra berry and 4g of salted plantain seed.
The preparation method comprises the following steps: taking all the medicinal materials according to the weight proportion, adding water until all the medicinal materials are not used, soaking for 30min, boiling with strong fire, decocting with slow fire for 30min, filtering, adding water again into the residues until all the medicinal materials are used, boiling with strong fire, decocting with slow fire for 20min, filtering, and combining the filtrates of the two filtering.
Example 2
A Chinese medicinal decoction for treating obesity type oligospermia is prepared from the following raw materials: 6g of ginseng, 6g of astragalus, 1g of bupleurum, 6g of angelica, 20g of bighead atractylodes rhizome, 1g of cimicifuga foetida, 1g of dried orange peel, 10g of poria cocos, 5g of pinellia ternate, 12g of fried semen cuscutae, 12g of medlar, 6g of raspberry, 1g of shizandra berry and 2g of salted plantain seed.
The preparation method comprises the following steps: taking all the medicinal materials according to the weight proportion, adding water until all the medicinal materials are not used, soaking for 30min, boiling with strong fire, decocting with slow fire for 35min, filtering, adding water again into the residues until all the medicinal materials are used, boiling with strong fire, decocting with slow fire for 15min, filtering, and combining the filtrates of the two filtering.
Example 3
A Chinese medicinal decoction for treating obesity type oligospermia is prepared from the following raw materials: 9g of ginseng, 9g of astragalus, 3g of bupleurum, 9g of angelica, 30g of bighead atractylodes rhizome, 2g of cimicifuga foetida, 3g of dried orange peel, 15g of poria cocos, 9g of pinellia ternate, 16g of fried semen cuscutae, 16g of medlar, 8g of raspberry, 2g of shizandra berry and 4g of salted plantain seed.
The preparation method comprises the following steps: taking all the medicinal materials according to the weight proportion, adding water until all the medicinal materials are not used, soaking for 30min, boiling with strong fire, decocting with slow fire for 30min, filtering, adding water again into the residues until all the medicinal materials are used, boiling with strong fire, decocting with slow fire for 20min, filtering, and combining the filtrates of the two filtering.
Experimental example
The invention relates to an effect study for treating obesity oligospermia
1. Establishing obesity type oligospermia model and administration
Male C57BL/6J mice 7 weeks old were randomly divided into normal group, model group, and capsule-less group (positive group, 1.05 g/kg), and the high, medium and low dose groups (22.5, 11.3, 5.6g crude drug/kg, respectively) of example 1 of the present invention were 10, 5, 2.5 times the human dosage of 135g crude drug/day calculated as kg body weight. Except for the normal group, the other groups were fed with high-fat feed for 12 weeks to prepare an obese oligospermia model. And starting the administration of each group of medicines by the dosage gastric lavage after 5 weeks of molding, and administering distilled water with equal volume by the normal group and the model group. Each group of animals was weighed weekly, and after 30 minutes from the last administration, isoflurane was inhaled for anesthesia, blood was taken from the eyeball, cervical dislocation was sacrificed, testis and epididymis were isolated, and relevant index detection was performed.
2. Index detection and result analysis
(1) Body weight measurement, calculation of testis, epididymal index and fat index
(2) Cleaning epididymis, peeling adipose tissue, placing into a beaker containing 1mL of preheated physiological saline at 37 ℃, transversely and longitudinally cutting 6-8 knives along the tail end of epididymis by using ophthalmic scissors, placing into a 37 ℃ water bath incubator for incubation for 10min, allowing sperm to free from the epididymis tail, and filtering by a 300-mesh filter screen to obtain a sperm suspensionThe temperature of the solution was maintained at 37 ℃. Dipping a drop of sperm suspension into a counting cell in the center of a Markler sperm counting plate, observing the number of sperm (n) in 10X 10 square by a 200-time optical microscope, wherein the number of sperm per milliliter is n X10 6 . Each mouse was observed three times, one square at a time, the total number of sperm was counted, and sperm quality was rated. The grading criteria are as follows: (a) a rapid linear forward motion, a linear motion; (b) Slowly moving forward in a straight line or moving forward in a slow way; (c) non-forward movement or in-situ tremor, in-situ movement; (d) not active, not moving. Calculating sperm viability,% = (a+b+c)/(a+b+c+d) ×100%; the number of sperm moving forward was counted, and sperm motility was calculated as motility/% = (a+b)/(a+b+c+d) ×100%.
(3) Serum hormone assay the centrifuged mouse serum was taken at 10 μl and analyzed for total cholesterol (Total Cholesterol, TC) and Triglyceride (TG) content using a fully automatic biochemical analyzer. Testosterone (Testosterone, T) and Leptin (Leptin, lep) hormone levels were determined using ELISA kit instructions.
(4) Testicular tissue HE observation of pathological changes testicular tissue was taken, 4% paraformaldehyde was fixed, paraffin embedded sections were cut, and HE staining was performed to observe pathological changes.
(5) Analysis of results:
as shown in fig. 1, mice body weight increased significantly (P < 0.01) after high fat diet feeding. Mice body weight was significantly reduced (P <0.05, P < 0.01) following administration of the present invention and also few capsules compared to the model group. Of these, the high dose group and the still few capsules of the present invention had the most pronounced effect on weight loss, with no statistical difference between the two groups.
As shown in FIG. 2, after the high fat feed is fed, the fat in the mice is obviously increased, and the fat has statistical significance (P < 0.001). Compared to the model group, abdominal fat was significantly reduced (P < 0.001) after administration of the present invention and also few capsules. Compared with few capsules, the high-dose lipid-lowering capacity of the invention is equivalent to that of the capsule, and the fat coefficient is not obviously different.
As shown in fig. 3A-3B, after the high fat feed is fed, the sperm density and activity of the mice in the model group are significantly reduced, and the difference of the sperm density and activity from the normal control group has statistical significance (P < 0.001). Compared with the model group, the invention and the few capsules have obviously increased sperm density and activity (P <0.05, P <0.01, P < 0.001) after gastric administration, and sperm quality is up-regulated. Compared with few capsules, the sperm density and activity of the high-dose group are obviously improved, but the difference has no statistical significance.
As shown in fig. 4A-4B, after the high-fat feed is fed, the TC and TG contents of mice in the model group are obviously increased (P < 0.05), and compared with the mice in the model group, the high-dose intragastric administration of the invention obviously reduces the TC and TG contents (P < 0.05), and the reduction effect of few capsules on TC and TG is not statistically significant. As shown in fig. 4C-4D, testosterone and leptin levels in serum of mice were tested, testosterone levels were significantly reduced (P < 0.05) in the model group, testosterone levels were significantly increased (P < 0.01) in the less capsule group, testosterone levels were significantly reduced (P <0.01, P < 0.001) and leptin levels were significantly decreased (P <0.05, P < 0.001) in the present group after administration, compared to the normal control group, testosterone and leptin levels were best restored after the high dose and less capsule treatment, and there was no statistical difference between the two groups.
As shown in FIG. 5, the cells of each grade in the testis tissue of the normal control mice are orderly arranged, the structure is complete, the number of the cells is large, the basal lamina is tightly combined with the cells, and a large amount of sperms are gathered in the lumen. Compared with the normal group, the testis tissue of the model group has wide vacuolation of spermatogenic, primary and secondary spermatogenic cells, loose and disordered arrangement of the spermatogenic cells at each level, reduced layer number, open lumen and reduced number of central mature sperms. The pathological condition of testis tissue of the mice in the group and the few capsules is obviously improved, cavitation is reduced, the raw sperm cells are orderly arranged, and the sperm density in the lumen is increased, wherein the pathological condition in testis tissue is obviously improved by the high-dose group and the few capsules.
In addition, the effect study on treating obesity type oligospermia was also carried out on the traditional Chinese medicine compounds of example 2 and example 3, and the conclusion is basically consistent with example 1. The invention has definite curative effect on obesity oligospermia and has wide clinical application prospect.
The preferred embodiments of the present invention have been described in detail above, but the present invention is not limited to the specific details of the above embodiments, and various simple modifications can be made to the technical solution of the present invention within the scope of the technical concept of the present invention, and all the simple modifications belong to the protection scope of the present invention.
Claims (10)
1. A traditional Chinese medicine compound for treating obesity oligospermia is characterized in that the preparation raw materials of the traditional Chinese medicine compound comprise the following components:
ginseng, astragalus root, bupleurum, angelica, bighead atractylodes rhizome, cimicifuga rhizome, dried orange peel, poria cocos, pinellia tuber, fried dodder, medlar, raspberry, shizandra berry and salted plantain seed.
2. The traditional Chinese medicine compound for treating obesity oligospermia according to claim 1, which is characterized by comprising the following raw materials in parts by weight:
6-9 parts of ginseng, 6-9 parts of astragalus, 1-3 parts of radix bupleuri, 6-9 parts of angelica, 20-30 parts of bighead atractylodes rhizome, 1-2 parts of cimicifuga foetida, 1-3 parts of dried orange peel, 10-15 parts of poria cocos, 5-9 parts of pinellia ternate, 12-16 parts of fried semen cuscutae, 12-16 parts of medlar, 6-8 parts of raspberry, 1-2 parts of schisandra chinensis and 2-4 parts of salted plantain seed.
3. The traditional Chinese medicine compound for treating obesity oligospermia according to claim 1, which is characterized by comprising the following raw materials in parts by weight:
9 parts of ginseng, 9 parts of astragalus, 3 parts of bupleurum, 9 parts of angelica, 30 parts of bighead atractylodes rhizome, 2 parts of cimicifuga foetida, 3 parts of dried orange peel, 15 parts of poria cocos, 9 parts of pinellia ternate, 16 parts of fried semen cuscutae, 16 parts of medlar, 8 parts of raspberry, 2 parts of shizandra berry and 4 parts of salted plantain seed.
4. The traditional Chinese medicine compound for treating obesity oligospermia according to one of claims 1 to 3, wherein the astragalus is astragalus root.
5. The Chinese herbal compound for treating obesity oligospermia according to any one of claims 1 to 3, wherein the dosage form of the Chinese herbal compound is selected from any one of decoction, granules, pills, paste, tablets and capsules.
6. The Chinese herbal compound for treating obesity oligospermia according to claim 5, wherein the Chinese herbal compound is in a form of decoction.
7. A preparation method of a traditional Chinese medicine decoction for treating obesity oligospermia is characterized by comprising the following steps: the components are taken according to the following weight proportion: 6-9 parts of ginseng, 6-9 parts of raw astragalus, 1-3 parts of radix bupleuri, 6-9 parts of angelica, 20-30 parts of bighead atractylodes rhizome, 1-2 parts of cimicifuga foetida, 1-3 parts of dried orange peel, 10-15 parts of poria cocos, 5-9 parts of pinellia ternate, 12-16 parts of fried semen cuscutae, 12-16 parts of medlar, 6-8 parts of raspberry, 1-2 parts of schisandra chinensis and 2-4 parts of salicornia asiatica, decocting in water, and filtering to obtain filtrate.
8. The preparation method according to claim 7, wherein the preparation method is: soaking the components in water until the components are soaked, decocting for 30-35 min, filtering, adding water again to the filter residue until the components are soaked, re-decocting for 15-20 min, filtering, and combining the filtrates obtained by the two filtering.
9. The use of a herbal compound according to any one of claims 1 to 6 for the manufacture of a medicament for the treatment of obesity oligospermia.
10. The use of a herbal compound according to any one of claims 1 to 6 for the manufacture of a medicament for the treatment of obesity.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311010577.6A CN116785369A (en) | 2023-08-09 | 2023-08-09 | Traditional Chinese medicine compound for treating obesity type oligospermia, preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311010577.6A CN116785369A (en) | 2023-08-09 | 2023-08-09 | Traditional Chinese medicine compound for treating obesity type oligospermia, preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116785369A true CN116785369A (en) | 2023-09-22 |
Family
ID=88039829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311010577.6A Pending CN116785369A (en) | 2023-08-09 | 2023-08-09 | Traditional Chinese medicine compound for treating obesity type oligospermia, preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116785369A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101049418A (en) * | 2007-05-16 | 2007-10-10 | 北京艺信堂医药研究所 | Prepared Chinese medicine for treating barrenness caused by lack of sperm |
| CN101129696A (en) * | 2007-08-24 | 2008-02-27 | 济南市第三人民医院 | Chinese patent medicine for treating aspermia or oligospermia and method of preparing the same |
| CN115192656A (en) * | 2022-07-21 | 2022-10-18 | 上海中医药大学附属龙华医院 | Traditional Chinese medicine composition for treating oligospermia and preparation method and application thereof |
-
2023
- 2023-08-09 CN CN202311010577.6A patent/CN116785369A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101049418A (en) * | 2007-05-16 | 2007-10-10 | 北京艺信堂医药研究所 | Prepared Chinese medicine for treating barrenness caused by lack of sperm |
| CN101129696A (en) * | 2007-08-24 | 2008-02-27 | 济南市第三人民医院 | Chinese patent medicine for treating aspermia or oligospermia and method of preparing the same |
| CN115192656A (en) * | 2022-07-21 | 2022-10-18 | 上海中医药大学附属龙华医院 | Traditional Chinese medicine composition for treating oligospermia and preparation method and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| 丁劲;张耀圣;商建伟;李曰庆;柴立民;李宪瑞;盛文;韦翊;马健雄;: "益肾健脾方对少弱精子症小鼠模型睾丸生精功能和血清性激素水平的影响", 环球中医药, vol. 9, no. 11, 6 November 2016 (2016-11-06), pages 1311 * |
| 王桐生;黄金玲;吴德玲;刘向国;乔磊;陈寒;李东东;: "补肾益精胶囊对少弱精症模型大鼠精子数量、质量、Ca~(2+)含量及性激素水平影响", 中国医院药学杂志, vol. 32, no. 24, 30 December 2012 (2012-12-30), pages 2 - 3 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104645132B (en) | A kind of Chinese medicine composition that treating diabetic nephropathy, preparation method, Chinese medicine preparation and application | |
| CN104888157A (en) | Traditional Chinese medicine preparation for treating hysteromyoma and preparation method thereof | |
| CN105267559A (en) | Diabetic peripheral neuropathy treatment medicine and manufacturing method thereof | |
| CN116785369A (en) | Traditional Chinese medicine compound for treating obesity type oligospermia, preparation method and application thereof | |
| CN102309705B (en) | Medicine for reducing serum uric acid, preparation method thereof and purpose thereof | |
| CN104524292A (en) | Application of traditional Chinese medicine preparation in preparation of medicament for treating obesity | |
| CN104645031A (en) | Traditional Chinese medicine preparation for treating type II diabetes and preparation method thereof | |
| CN100467043C (en) | Chinese medicine for treating osteoporosis and its preparation | |
| CN105288501A (en) | Traditional Chinese medicine composition containing folium artemisiae argyi and treating obesity | |
| CN102198251B (en) | Chinese medicinal composition for treating climacteric syndrome and preparation method thereof | |
| CN104547738A (en) | Traditional Chinese medicine preparation for treating obesity and preparation method of traditional Chinese medicine preparation | |
| CN104645054A (en) | Traditional Chinese medicine preparation for treating facioplegia and preparation process thereof | |
| CN104645003A (en) | Traditional Chinese medicine preparation for treating asthma and preparation method of traditional Chinese medicine preparation | |
| CN104352797A (en) | Traditional Chinese medicine for treating advanced lung cancer and application of traditional Chinese medicine | |
| CN104689010A (en) | Chinese traditional medicine preparation for treatment of kidney deficiency and preparation technology thereof | |
| CN115554372B (en) | Traditional Chinese medicine for treating primary fibromyalgia syndrome and preparation method and application thereof | |
| CN115779046B (en) | Traditional Chinese medicine composition, traditional Chinese medicine preparation and application for preventing and treating diabetes | |
| CN108514627A (en) | A kind of Chinese medicine composition for treating chronic urticaria | |
| CN116688053B (en) | Traditional Chinese medicine composition for improving tumour cachexia and muscular atrophy, preparation method and application | |
| CN115708859B (en) | Pharmaceutical composition for treating allergic rhinitis and preparation method thereof | |
| CN106728836B (en) | Traditional Chinese medicine composition for treating infantile viral myocarditis and preparation method thereof | |
| CN103381205B (en) | Centipede pseudo-ginseng extract product is at the application prepared in medicine against intestinal adhesion and medicine thereof | |
| CN105288498A (en) | Method for preparing folium artemisiae argyi-contained traditional Chinese medicine preparation capable of treating obesity | |
| CN105749159A (en) | Application of traditional Chinese medicine for treating psoriasis in preparation of medicine for treating multiple sclerosis | |
| CN108014300B (en) | Traditional Chinese medicine composition preparation and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |